Coloplast axed traditional budgeting process: "It wasn't promoting growth"

The Covid-19 pandemic has shown that the budgeting process can quickly become redundant. A lesson Coloplast had already learned from the financial crisis.

"We concluded that there was a massive amount of resources being wasted across the organisation as a result our model," Executive BVVP and CFO Anders Lonning-Skovgaard says of the traditional budgeting process. | Photo: Niels Hougaard/ERH

BY LEONORA BECK AND SIGNE FERSLEV, TRANSLATED BY DANIEL PEDERSEN

Published: 09.09.21 at 15:25

Before 2009, Coloplast's budgeting process often took up to half a year, seizing the time and effort of countless key people in the organization.

Several hundreds of Coloplast leaders met every yet in an auditorium in north of Copenhagen to tune budget constraints. Everybody had to assess how much money their individual unit was going to spend – on everything from HR to financing – every month for the next 12 months. Thousands of fields in forms were filled by function, region and country.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Foto: Rob Acket/EMA

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

WS Audiology still chewing over listing of online hearing company

Foto: WS Audiology / PR

The hearing giant is still mulling over the independent listing of Hear.com.

CEO at WSA: No clarity on EQT exit plans yet

Foto: WS Audiology / PR

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Oticon: Covid-19 led to debates about product launches

Foto: Oticon/PR

The unpredictable world situation in the spring of 2020 meant that the timing of product launches was frequently discussed at Demant-owned Oticon, located in Denmark.

EU Commission ends Danish HERA dreams – but could provide new opportunities for the pharmaceutical industry

One of the European Commissions Vice-Presidents, Margaritis Schinas (left), presented the HERA proposal on Thursday, alongside with Commissioner for Health and Food Safety Stella Kyriakides and Commissioner for Internal Market Thierry Breton. | Foto: FRANCOIS WALSCHAERTS/AFP / AFP

With a budget potentially exceeding EUR 47.1bn (DKK 350bn), the EU Commission wants to establish a new agency to ward against future health crises. While the financial makeup is uncertain, good news for future clinical trials might be on the way.

Further reading

Related articles